{"news_desk": "Business", "print_page": "1", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By ANDREW POLLACK and JULIE CRESWELL", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}, {"rank": 2, "role": "reported", "firstname": "Julie", "organization": "", "lastname": "CRESWELL"}]}, "abstract": "Profile of Turing Pharmaceuticals executive Martin Shkreli, who became symbol of pharmaceutical price gouging after company raised price on drug Daraprim from $13.50 per pill to $750; those who know Shkreli say he is intelligent and has talent in finding lucrative drugs on market, but he is also no stranger to public controversy.", "type_of_material": "News", "word_count": "1421", "lead_paragraph": "After raising the cost for a drug used to treat serious parasitic infections to $750 a tablet, from $13.50, Martin Shkreli of Turing Pharmaceuticals says he will sell it for less to ease public anger.", "pub_date": "2015-09-23T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Martin Shkreli, the Mercurial Man Behind the Drug Price Increase That Went Viral  ", "print_headline": "The Man Behind the Drug Price Increase"}, "snippet": "After raising the cost for a drug used to treat serious parasitic infections to $750 a tablet, from $13.50, Martin Shkreli of Turing Pharmaceuticals says he will sell it for less to ease public anger.", "multimedia": [{"height": 126, "url": "images/2015/09/23/business/23SHKRELI/23SHKRELI-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/09/23/business/23SHKRELI/23SHKRELI-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 720, "url": "images/2015/09/23/business/23SHKRELI/23SHKRELI-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "720", "xlarge": "images/2015/09/23/business/23SHKRELI/23SHKRELI-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/09/23/business/23SHKRELI/23SHKRELI-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/09/23/business/23SHKRELI/23SHKRELI-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/09/23/business/big-price-increase-for-an-old-drug-will-be-rolled-back-turing-chief-says.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Shkreli, Martin (1983- )", "name": "persons"}, {"rank": "2", "is_major": "Y", "value": "Turing Pharmaceuticals AG", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}], "blog": [], "_id": "5601e40138f0d82db05b95c6", "source": "The New York Times"}